Understanding how dengue vaccines and infections create lasting immunity
Durability and mechanisms of dengue vaccine and infection mediated immunity
['FUNDING_OTHER'] · ST. LOUIS VA MEDICAL CENTER · NIH-11043316
This study is looking at how well the TDV/TAK003 dengue vaccine helps your immune system fight off dengue compared to getting the virus naturally, especially for people who haven't been infected before, and it will track your immune response and health over the years to see how long that protection lasts.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ST. LOUIS VA MEDICAL CENTER (nih funded) |
| Locations | 1 site (St. Louis, UNITED STATES) |
| Trial ID | NIH-11043316 on ClinicalTrials.gov |
What this research studies
This research investigates the immune responses generated by the TDV/TAK003 dengue vaccine and how they compare to immunity developed after natural dengue infections. It focuses on the durability of the immune response, particularly the production of specific antibodies and T cells that can protect against future infections. The study aims to understand the mechanisms behind antibody-dependent enhancement (ADE) of disease and how the vaccine can provide safe and effective protection, especially for those who have never been infected before. Patients may be monitored over several years to assess their immune responses and overall health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have never been infected with dengue virus and are at risk of exposure, such as veterans or residents in endemic areas.
Not a fit: Patients who have previously been infected with dengue virus may not benefit from this research as the focus is on those who are seronegative.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer dengue vaccine that provides long-lasting immunity for individuals, particularly those at risk of severe dengue disease.
How similar studies have performed: Previous research has shown promising results with the TDV/TAK003 vaccine, indicating it may provide a novel and effective approach to dengue prevention.
Where this research is happening
St. Louis, UNITED STATES
- ST. LOUIS VA MEDICAL CENTER — St. Louis, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GEORGE, SARAH — ST. LOUIS VA MEDICAL CENTER
- Study coordinator: GEORGE, SARAH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.